# Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV

> **NCT03004625** · PHASE3 · COMPLETED · sponsor: **Kaohsiung Medical University Chung-Ho Memorial Hospital** · enrollment: 70 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** daclatasvir
- **DRUG:** asunaprevir
- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT03004625
- **Lead sponsor:** Kaohsiung Medical University Chung-Ho Memorial Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11
- **Primary completion:** 2018-04
- **Final completion:** 2018-04
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2019-01-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03004625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03004625, "Daclatasvir, Asunaprevir Plus Ribavirin for HCV Genotype 1b Without NS5A RAV". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03004625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*